Wave Life Sciences Ltd.
WVE · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -1.77 | -0.77 | 0.03 | -0.12 |
| FCF Yield | -3.66% | -4.35% | -4.81% | -2.19% |
| EV / EBITDA | -20.37 | -17.39 | -22.96 | 68.50 |
| Quality | ||||
| ROIC | -34.39% | -30.48% | -23.85% | 9.23% |
| Gross Margin | 100.00% | 74.76% | 76.41% | 100.00% |
| Cash Conversion Ratio | 0.83 | 0.91 | 1.34 | -1.49 |
| Growth | ||||
| Revenue 3-Year CAGR | 8.51% | 36.97% | 91.99% | 209.61% |
| Free Cash Flow Growth | 3.03% | 26.72% | -44.52% | 6.67% |
| Safety | ||||
| Net Debt / EBITDA | 3.42 | 3.69 | 4.61 | -11.01 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 118.30 | -584.25 | -597.14 | 1.53 |